A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
Tests in rats showed that the designed mos-tri-RBD, whether used alone or as a booster shot, elicited potent cross-neutralizing antibodies against not only Omicron but also other immune-evasive variants of SARS-CoV-2.
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
- BiologyEnvironmental Research
Omicron variant infection and the associated immunological scenario
Vaccines alone will not prevent COVID-19 outbreaks among migrant workers—the example of meat processing plants
- MedicineClinical Microbiology and Infection
A potent SARS-CoV-2 neutralizing antibody recognizing a conserved epitope with broad mutant variant and SARS-CoV activity
It is believed that ABP-310 has therapeutic promise not only against the current SARS-CoV-2 variants but would be expected to maintain efficacy against future variants and possibly even novel coronaviruses.
Advances in the Omicron variant development
- BiologyJournal of internal medicine
This review provides an overview regarding the molecular profile of the Omicron variant, epidemiology, transmissibility, the impact on vaccines, as well as vaccine escape, and the pharmacological agents able to block the endocellular entry of SARS‐CoV‐2 or to inhibit its viral replication.
Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions
- Biology, MedicineSignal Transduction and Targeted Therapy
A variety of possible microbiota-based prophylaxes and therapies for COVID-19 and PACS are reviewed, including fecal microbiota transplantation (FMT), probiotics, prebiotics, microbiota-derived metabolites, and engineered symbiotic bacteria.
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
- BiologyNature medicine
This study tested a panel of anti-receptor-binding domain monoclonal antibodies corresponding to those in clinical use by Vir Biotechnology, AstraZeneca, Regeneron, Eli Lilly, and Celltrion for their ability to neutralize an infectious B.1.1,1.529 Omicron isolate and suggested that several, but not all, of the antibodies inclinical use might lose efficacy against the B. 1.1.,1.
Assessment of Attitudes, Main Concerns and Sources of Knowledge Regarding COVID-19 Vaccination in Poland in the Unvaccinated Individuals—A Nationwide Survey
The public is primarily concerned about adverse events of vaccines and the lack of appropriate tests of the products used, so the Internet is the main source of knowledge about the COVID-19 vaccination, so it should be focused on during vaccination campaigns.
Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
- Medicine, BiologyVaccines
This study analyzed binding and neutralizing antibody titers up to 6 months after standard vaccination with BNT162b2 in SARS-CoV-2 naïve patients receiving hemodialysis to identify risk factors for the absence of humoral immune responses at 6 months and found the strongest association for vanishing immune responses was low serum albumin.
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies
In vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19.